TD Asset Management
SLNO

TD Asset Management’s Soleno Therapeutics SLNO Stock Holding History

TD Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,622
Closed -$862K – 1293
2025
Q4 		$862K Sell
18,622
-95,130
-84% -$5.22M ﹤0.01% 1116
2025
Q3 		$7.69M Buy
113,752
+13,942
+14% +$1.03M 0.01% 714
2025
Q2 		$8.36M Buy
99,810
+25,800
+35% +$1.93M 0.01% 680
2025
Q1 		$5.29M Buy
74,010
+14,276
+24% +$695K ﹤0.01% 776
2024
Q4 		$2.69M Sell
59,734
-5,200
-8% -$269K ﹤0.01% 925
2024
Q3 		$3.19M Buy
64,934
+7,400
+13% +$354K ﹤0.01% 896
2024
Q2 		$2.35M Buy
57,534
+36,534
+174% +$1.55M ﹤0.01% 945
2024
Q1 		$899K Buy
+21,000
New +$950K ﹤0.01% 1185

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

TD Asset Management's SLNO Position: Q1 2026 in Review

TD Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 18,622 shares — an estimated $862K sold.

TD Asset Management first reported a position in SLNO in Q1 2024 and held it in 8 quarters. The position peaked at $8.36M in Q2 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • TD Asset Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 18,622 Soleno Therapeutics shares in Q1 2026, an estimated $862K.
  • TD Asset Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 8 quarters.
  • TD Asset Management's Soleno Therapeutics position peaked at $8.36M in Q2 2025.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.